Opko Health, Inc.

295 articles with Opko Health, Inc.

• OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

  5/9/2022

  OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases.

• OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022

  5/5/2022

  OPKO Health, Inc. plans to report operating and financial results for the three months ended March 31, 2022 after the close of the U.S. financial markets on Monday, May 9, 2022.

• Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease

  3/1/2022

  Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, to assist in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency who may be eligible to participate in a Phase 3 clinical trial.

• OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

  2/24/2022

  OPKO Health, Inc. reports business highlights and financial results for the three months ended December 31, 2021.

• OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

  2/17/2022

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financial markets on Thursday, February 24, 2022.

• Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

  2/15/2022

  Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.

• RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

  2/3/2022

  OPKO Health, Inc. announces that Vifor Fresenius Medical Care Renal Pharma has initiated the commercial launch of RAYALDEE® in Germany, the first launch of RAYALDEE outside the U.S. VFMCRP is OPKO’s commercial partner for RAYALDEE in Europe and selected markets outside the U.S.

• 

  Pfizer and OPKO's Growth Hormone Deficiency Drug Denied by FDA

  1/24/2022

  FDA rejected OPKO's once-weekly human growth hormone, somatrogon, which it co-developed with Pfizer for the treatment of growth hormone deficiency (GHD) in pediatric patients.

• Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

  1/18/2022

  Sema4, an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company, announced they have signed a definitive agreement for Sema4 to acquire OPKO’s wholly owned subsidiary, GeneDx, Inc., a leader in genomic testing and analysis, from OPKO.

• OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

  OPKO Health, Inc. announced that management will be participating in the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022.

• OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

  12/23/2021

  OPKO Health, Inc. (NASDAQ: OPK) announces preliminary topline results from its Phase 2 trial with RAYALDEE ® to treat mild-to-moderate COVID-19.

• 

  Former Scripps and Humira Leader Richard Lerner Passes Away

  12/7/2021

  Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.

• OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/29/2021

  OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30 through December 2, 2021.

• OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021

  10/25/2021

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 28, 2021.

• GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes

  9/21/2021

  GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, announced it has completed clinical genetic exome sequencing for more than 300,000 patients, making the company's dataset the largest of its kind in the world.

• OPKO Health to Participate in Two Upcoming Investment Conferences

  8/30/2021

  OPKO Health, Inc. announced that management will be participating in two upcoming virtual investor conferences.

• OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients

  8/30/2021

  OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE ® as a treatment for mild-to-moderate COVID-19.

• OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results

  7/29/2021

  OPKO Health, Inc. reports business highlights and financial results for the three months ended June 30, 2021.

• OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021

  7/20/2021

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 29, 2021.

• OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference

  7/8/2021

  OPKO Health, Inc. announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021.